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While rapid on-site evaluation (ROSE) is considered to be an additional tool to optimize the 
yield of tissue acquisition during EUS-guided FNA of the gastrointestinal tract,1,2 it is not readily 
available at all times while performing these procedures. We reviewed twenty-seven EUS-guided 
FNA procedures done at our institution in Tripoli central hospital with general working center 
restrictions due to local COVID-19 prevention protocols. Approximately 92.6 % of tissue 
adequacy was achieved despite the lack of ROSE which is comparable to ROSE-based tissue 
acquisition results. This is a small-size retrospective chart review study to illustrate the optimal 
tissue adequacy during EUS-guided FNA of the upper gastrointestinal tract in a suboptimal 
hospital setting, lack of ROSE and merely utilizing visual inspection of those specimens by the 








The Endoscopic Ultrasound (EUS) machine is a combination of an endoscope with an ultrasound 
device that has been used in the diagnostic and therapeutic assessment of the gastrointestinal 
system and has changed the approach of gastrointestinal pathologies in modern medicine.3 
Endoscopic ultrasound-guided-fine needle aspiration (EUS-guided FNA) is now performed 
routinely in many advanced endoscopy centers around the globe and has enhanced the ability to 
diagnose pancreatic pathologies.4 The development of linear ultrasound endoscopes led to EUS-
FNA being carried out with great precision in real-time, with the FNA needle being visualized 
throughout the procedure. It has been found that EUS-guided FNA is most useful in making an 
initial tissue diagnosis of malignancy, carrying a high diagnostic value with a low complication 
rate. It is also cost-effective in accurately preoperatively staging patients with pancreatic 
solid masses and has greatly improved the prognosis by reducing unnecessary surgical 
interventions and eventual morbidity and mortality in patients with advanced cancer.6,7 Early 
diagnosis of pancreatic tumors is essential to identifying patients who are eligible for surgical 
intervention. Therefore, EUS-guided FNA is considered an important tool, since it is capable of 
identifying neoplasms less than 3mm that are rarely noticed by other imaging modalities.10 EUS-
guided FNA also has limitations, however, and imperfections,3 as the utility of EUS in obtaining 
pancreatic samples or tissue of any gastrointestinal pathology depends on multiple factors. These 
include the physician’s experience and training and adequate supervision and rapid on-site 
evaluation (ROSE), which provides a real-time evaluation of the acquired specimen. 
Furthermore, needle size, patient sedation, patient age, past medical history, and the location, 
size, and consistency of the lesion must all be considered. 
 
A medical literature review to evaluate the role of EUS-guided FNA for diagnosis of solid 
pancreatic masses showed 78-95% sensitivity, 75-100% specificity, 98-100% positive predictive 
value, 46-80% negative predictive value (NPV), and 78-95% accuracy. The reported 
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complications rate of EUS-guided FNA for pancreatic solid masses was 0-2%, although the 




This is a retrospective chart review of 27 patients that had undergone FNA-guided EUS from 
the beginning of March until the end of August 2020. These cases occurred during the COVID-
19 pandemic, which meant that ROSE was not being used during the evaluation of these 
patients. Our histopathology department provided histological reports for all of the EUS-guided 
FNA samples, which were read by the same histopathologists. Descriptive analysis and cross-




This study reviewed a retrospective chart, as opposed to conducting randomized control trials, 
which is known to have more reliable results. A larger cohort of the reviewed cases, instead of 
the actual used number, would have more definitively assessed the small differences in 
diagnostic yield and allowed a better understanding of the reliability and enhanced measurement 
quality of the tissues acquired. Due to the pandemic prevention protocol in our center, several 
EUS cases were postponed. Additionally, there were several technical and clinical obstacles 
during those procedures, including the unavailability of an anesthesiologist physician or CRNA, 
an absence of staff training on the EUS machinery, and assistance techniques which forced the 




All procedures were done in a tertiary center located in Tripoli and were performed by a trained 
Libyan physician in collaboration with a qualified U.S. physician. FNAs were obtained using 
both the standard and fanning techniques, with and without suction, using a 20cc syringe. No 
adverse events were reported during or immediately after those procedures. Patient ages ranged 
between 18 and 77 years old with a mean age of 55 years, with gender distribution showing an 
almost equal representation of male and female patients.  
 
The vast majority of specimens were collected using 22-gauge needles, with 19-gauge needles 
also being used. All of the samples were collected in both containers and slides which were air-
dried on site. All samples were visually inspected by the operator to assess tissue adequacy 
before they were eventually sent to the histopathology laboratory and ultimately analyzed by 
three experienced histopathologists. Among the 42 patients who were required to undergo a EUS 
evaluation as a result of prior imaging findings that necessitated further evaluation, EUS-guided 
FNA was done for only 28 of them. Out of those 28 cases, we were able to collect 27 results, as 
we were unable to follow up with one patient. Within those 27 specimens, 21 were confirmed to 
be adenocarcinomas. All 21 of those patients were referred to an oncologist for further 
management. 
 
In terms of tissue acquisition, all of the 27 specimens contained sufficient tissue. As most of the 
patients that received EUS-guided FNA had radiological findings that suggested malignancy, 
FNA results showed a sensitivity of 77.8% and a positive predictive value of 100%. Six results 
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were considered to be inconclusive as the histopathology reports did not match the radiological 
findings or the surgical biopsy results, even though those tissue specimens were adequate.  
Among the 27 specimens, 25 (92%) of them were in both conventional smears and cell block 
samples. The remaining two specimens contained only cells as noted by the conventional smear 
method (8%). One specimen that was obtained from the gallbladder was inconclusive, while the 
other one was confirmed to be malignancy of the pancreatic head. This confirms the significance 
of the tissue obtaining technique implemented throughout the procedure. According to the 
histopathology results, the most identified neoplasm was adenocarcinoma (40+%). Almost 20% 
of the diagnosed cases were undifferentiated malignant epithelial neoplasms. There was only one 
sample that had extensive cellular destruction during preparation. 
 
25-gauge needles are considered the most optimal recommended needle size for the sampling of 
pancreatic masses and are known to have a higher negative predictive value and cause less 
tissue damage than standard 22-gauge needles.5 The majority of our specimens were collected 
using 22-gauge needles, although 19-gauge needles were also used.  
 
One prospective randomized study 8 aimed to compare the diagnostic yield of 22-gauge and 25-
gauge needles. It was found that cytology was diagnostic in 91.6% of cases, while no 
statistically significant differences were found between the two groups when a similar number 
of passes were performed in both arms.8 Our study suggests similar findings to those in the 
above study. 
 
It has been explained that EUS-guided FNA is limited by the lack of cytology expertise. It has 
also been foreseen that EUS-guided fine needle biopsy (FNB) may likely overcome these 
limitations by moving the practice of EUS from cytology to histology, which will result in 




We concluded that our results of tissue acquisition and analysis with the standard (off-site) 
histopathology techniques are comparable to those in more developed centers where ROSE is 
readily available. Although the site in Tripoli lacked high-standard training and experienced a 
significant shortage of properly equipped facilities, most of the patients who received 
management in our care provided adequate tissue samples collected mainly using 22-gauge 
needles with results that confirm or exclude neoplasms. According to the previously presented 
data, with consideration of the working clinical conditions, our results retained reliability of 
sample acquisition and efficacy in the detection of pancreatic and hepatobiliary tumors. We 
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